A Phase II Trial of a WT-1 Vaccine in Patients with Acute Myeloid Leukemia

Full Title

Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) from Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)


Wilms Tumor 1 (WT-1) is a gene that is involved in the normal development of the kidneys and other organs. However, when the WT-1 gene becomes abnormal, it can make proteins involved in the development of some cancers, including leukemia.

The purpose of this study is to evaluate the safety and effectiveness of a vaccine against the WT-1 protein which is designed to cause an immune response against acute myeloid leukemia (AML). The WT-1 vaccine is made up of protein pieces that the immune system can recognize as abnormal.

The vaccine will be evaluated in patients with AML that is in remission. Researchers want to determine if the WT-1 vaccine can eliminate any residual AML cells remaining in the body and prevent a recurrence of the disease.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be in first clinical remission of AML and have disease that tests positive for the WT-1 protein.
  • At least 4 weeks must have passed since completion of chemotherapy or radiation therapy and receipt of the first dose of the vaccine.
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Peter Maslak at 212 639-5518.